339,461 Shares in Olema Pharmaceuticals, Inc. $OLMA Purchased by SEB Asset Management AB

SEB Asset Management AB acquired a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the first quarter, HoldingsChannel.com reports. The fund acquired 339,461 shares of the company’s stock, valued at approximately $5,061,000.

A number of other institutional investors also recently added to or reduced their stakes in OLMA. Bain Capital Life Sciences Investors LLC increased its position in Olema Pharmaceuticals by 24.3% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock worth $212,716,000 after purchasing an additional 1,664,687 shares during the period. Paradigm Biocapital Advisors LP lifted its holdings in shares of Olema Pharmaceuticals by 11.0% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock valued at $188,604,000 after buying an additional 750,000 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Olema Pharmaceuticals by 87.1% in the 4th quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company’s stock valued at $167,901,000 after buying an additional 3,124,345 shares during the period. Vanguard Group Inc. boosted its stake in shares of Olema Pharmaceuticals by 11.4% in the fourth quarter. Vanguard Group Inc. now owns 3,561,355 shares of the company’s stock valued at $89,034,000 after buying an additional 364,035 shares in the last quarter. Finally, Deep Track Capital LP boosted its stake in shares of Olema Pharmaceuticals by 0.8% in the third quarter. Deep Track Capital LP now owns 3,470,172 shares of the company’s stock valued at $33,973,000 after buying an additional 27,339 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Trading Down 0.9%

NASDAQ:OLMA opened at $11.49 on Thursday. The company has a market capitalization of $1.00 billion, a PE ratio of -5.69 and a beta of 2.00. The company has a quick ratio of 10.88, a current ratio of 10.88 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals, Inc. has a 52-week low of $4.47 and a 52-week high of $36.26. The stock has a fifty day simple moving average of $11.69 and a 200-day simple moving average of $17.18.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, hitting the consensus estimate of ($0.52). On average, equities research analysts expect that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on OLMA. HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Friday, May 22nd. Wall Street Zen upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Friday, July 17th. Wolfe Research started coverage on shares of Olema Pharmaceuticals in a research note on Friday, March 27th. They set a “peer perform” rating on the stock. Finally, Guggenheim cut their price target on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $44.10.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.